Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ngm Biopharmaceuticals Inc
(NQ:
NGM
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ngm Biopharmaceuticals Inc
< Previous
1
2
Next >
NGM Bio Announces Closing of Tender Offer
April 05, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
March 19, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
March 13, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
February 27, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
February 26, 2024
From
Halper Sadeh LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT)
February 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
February 26, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
February 20, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 17, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
January 09, 2024
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
November 13, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in Upcoming Investor Conferences
November 07, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 02, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
October 11, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 03, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in Upcoming Investor Conferences
May 25, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 08, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
May 04, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
January 12, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
January 09, 2023
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
December 12, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
December 07, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
November 07, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
November 04, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
November 03, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
October 17, 2022
From
NGM Biopharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.